Through our research programs, we are addressing the barriers that are preventing safer treatments from reaching children. Our research strategy encompasses programs and funding that deliver results to save children NOW.
The third and final phase of CureSearch’s research strategy is the Catapult Awards program. These critical awards push forward high-potential research into clinical trials and ultimately drug development.
Catapult Awards – Active Grants
Catapult Awards will provide funding support up to $5 million for a two- to three-year award period for ‘clinic-ready’ projects.
2017/2018 APPLICATION CYCLE:
The General Catapult Award launched in October 2017 with a focus on Phase 1 or Phase 2 clinical trials testing novel, targeted agents or “repurposed” adult targeted agents for pediatric cancers. The application window is now closed and awards were announced in July 2018.
CureSearch continues to invest in large-scale awards to ensure sustainable research moves forward at an accelerated pace. We are proud to invest in work that will move the needle and impact the future of children’s treatments.
We’re excited to announce that two project awards slated for 2018/2019:
Upcoming Catapult Awards:
- Immunotherapy Catapult Award in partnership with the Parker Institute for Cancer Immunotherapy. Read more in our Press Room. – Fall 2018
- Molecular Targets Catapult Award – Fall 2019
Click here to be added to our mailing list to be the first to know about new RFAs.
Request for Applications: General Information
CureSearch Catapult Awards will provide support for projects that:
- Will advance promising therapies for pediatric cancer into or further along in clinical development
- Show a strong potential for future approval and commercialization
Highest priority will be given to projects that address areas of high unmet needs in pediatric cancer. Catapult Awards will provide funding support up to $5 million for a two- to three-year award period, for “clinic-ready” projects that fit the following parameters:
CureSearch won’t stop until more and less-toxic children’s cancer treatments are out of the lab and into the clinic and marketplace, ensuring more children live long, healthy and productive lives.
For more information on Catapult Awards, developing resources or future RFAs, contact:
National Director, Strategic Initiatives
Sarita Sastry, PhD
National Director, Research and Programs